Literature DB >> 24853936

The intersection of amyloid beta and tau at synapses in Alzheimer's disease.

Tara L Spires-Jones1, Bradley T Hyman2.   

Abstract

The collapse of neural networks important for memory and cognition, including death of neurons and degeneration of synapses, causes the debilitating dementia associated with Alzheimer's disease (AD). We suggest that synaptic changes are central to the disease process. Amyloid beta and tau form fibrillar lesions that are the classical hallmarks of AD. Recent data indicate that both molecules may have normal roles at the synapse, and that the accumulation of soluble toxic forms of the proteins at the synapse may be on the critical path to neurodegeneration. Further, the march of neurofibrillary tangles through brain circuits appears to take advantage of recently described mechanisms of transsynaptic spread of pathological forms of tau. These two key phenomena, synapse loss and the spread of pathology through the brain via synapses, make it critical to understand the physiological and pathological roles of amyloid beta and tau at the synapse.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24853936      PMCID: PMC4135182          DOI: 10.1016/j.neuron.2014.05.004

Source DB:  PubMed          Journal:  Neuron        ISSN: 0896-6273            Impact factor:   17.173


  218 in total

1.  Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment.

Authors:  R D Terry; E Masliah; D P Salmon; N Butters; R DeTeresa; R Hill; L A Hansen; R Katzman
Journal:  Ann Neurol       Date:  1991-10       Impact factor: 10.422

2.  Oligomeric amyloid beta associates with postsynaptic densities and correlates with excitatory synapse loss near senile plaques.

Authors:  Robert M Koffie; Melanie Meyer-Luehmann; Tadafumi Hashimoto; Kenneth W Adams; Matthew L Mielke; Monica Garcia-Alloza; Kristina D Micheva; Stephen J Smith; M Leo Kim; Virginia M Lee; Bradley T Hyman; Tara L Spires-Jones
Journal:  Proc Natl Acad Sci U S A       Date:  2009-02-19       Impact factor: 11.205

3.  Pathogenic forms of tau inhibit kinesin-dependent axonal transport through a mechanism involving activation of axonal phosphotransferases.

Authors:  Nicholas M Kanaan; Gerardo A Morfini; Nichole E LaPointe; Gustavo F Pigino; Kristina R Patterson; Yuyu Song; Athena Andreadis; Yifan Fu; Scott T Brady; Lester I Binder
Journal:  J Neurosci       Date:  2011-07-06       Impact factor: 6.167

Review 4.  Pathogenic protein seeding in Alzheimer disease and other neurodegenerative disorders.

Authors:  Mathias Jucker; Lary C Walker
Journal:  Ann Neurol       Date:  2011-10       Impact factor: 10.422

5.  Impaired spine stability underlies plaque-related spine loss in an Alzheimer's disease mouse model.

Authors:  Tara L Spires-Jones; Melanie Meyer-Luehmann; Jennifer D Osetek; Phillip B Jones; Edward A Stern; Brian J Bacskai; Bradley T Hyman
Journal:  Am J Pathol       Date:  2007-08-23       Impact factor: 4.307

6.  Amyloid-β oligomers induce synaptic damage via Tau-dependent microtubule severing by TTLL6 and spastin.

Authors:  Hans Zempel; Julia Luedtke; Yatender Kumar; Jacek Biernat; Hana Dawson; Eckhard Mandelkow; Eva-Maria Mandelkow
Journal:  EMBO J       Date:  2013-09-24       Impact factor: 11.598

7.  The neuropathology of older persons with and without dementia from community versus clinic cohorts.

Authors:  Julie A Schneider; Neelum T Aggarwal; Lisa Barnes; Patricia Boyle; David A Bennett
Journal:  J Alzheimers Dis       Date:  2009       Impact factor: 4.472

8.  Early changes in hippocampal Eph receptors precede the onset of memory decline in mouse models of Alzheimer's disease.

Authors:  Ana María Simón; Rakel López de Maturana; Ana Ricobaraza; Luis Escribano; Lucio Schiapparelli; Mar Cuadrado-Tejedor; Alberto Pérez-Mediavilla; Jesús Avila; Joaquín Del Río; Diana Frechilla
Journal:  J Alzheimers Dis       Date:  2009       Impact factor: 4.472

9.  Caspase-3 in the central nervous system: beyond apoptosis.

Authors:  Marcello D'Amelio; Morgan Sheng; Francesco Cecconi
Journal:  Trends Neurosci       Date:  2012-07-14       Impact factor: 13.837

Review 10.  A century of Alzheimer's disease.

Authors:  Michel Goedert; Maria Grazia Spillantini
Journal:  Science       Date:  2006-11-03       Impact factor: 47.728

View more
  348 in total

1.  Mitochondrial ATP synthase activity is impaired by suppressed O-GlcNAcylation in Alzheimer's disease.

Authors:  Moon-Yong Cha; Hyun Jin Cho; Chaeyoung Kim; Yang Ouk Jung; Min Jueng Kang; Melissa E Murray; Hyun Seok Hong; Young-Joo Choi; Heesun Choi; Dong Kyu Kim; Hyunjung Choi; Jisoo Kim; Dennis W Dickson; Hyun Kyu Song; Jin Won Cho; Eugene C Yi; Jungsu Kim; Seok Min Jin; Inhee Mook-Jung
Journal:  Hum Mol Genet       Date:  2015-09-10       Impact factor: 6.150

2.  Peptide dimer structure in an Aβ(1-42) fibril visualized with cryo-EM.

Authors:  Matthias Schmidt; Alexis Rohou; Keren Lasker; Jay K Yadav; Cordelia Schiene-Fischer; Marcus Fändrich; Nikolaus Grigorieff
Journal:  Proc Natl Acad Sci U S A       Date:  2015-09-08       Impact factor: 11.205

3.  Vildagliptine protects SH-SY5Y human neuron-like cells from Aβ 1-42 induced toxicity, in vitro.

Authors:  Alim Hüseyin Dokumacı; Mukerrem Betul Yerer Aycan
Journal:  Cytotechnology       Date:  2019-04-09       Impact factor: 2.058

4.  Peripheral Interventions Enhancing Brain Glutamate Homeostasis Relieve Amyloid β- and TNFα- Mediated Synaptic Plasticity Disruption in the Rat Hippocampus.

Authors:  Dainan Zhang; Alexandra J Mably; Dominic M Walsh; Michael J Rowan
Journal:  Cereb Cortex       Date:  2017-07-01       Impact factor: 5.357

5.  Differentiating Between Healthy Control Participants and Those with Mild Cognitive Impairment Using Volumetric MRI Data.

Authors:  Renée DeVivo; Lauren Zajac; Asim Mian; Anna Cervantes-Arslanian; Eric Steinberg; Michael L Alosco; Jesse Mez; Robert Stern; Ronald Killany
Journal:  J Int Neuropsychol Soc       Date:  2019-05-27       Impact factor: 2.892

6.  Novel methods for integration and visualization of genomics and genetics data in Alzheimer's disease.

Authors:  Nathan A Bihlmeyer; Emily Merrill; Yann Lambert; Gyan P Srivastava; Timothy W Clark; Bradley T Hyman; Sudeshna Das
Journal:  Alzheimers Dement       Date:  2019-03-29       Impact factor: 21.566

7.  Changes in Synaptic Proteins Precede Neurodegeneration Markers in Preclinical Alzheimer's Disease Cerebrospinal Fluid.

Authors:  Alberto Lleó; Raúl Núñez-Llaves; Daniel Alcolea; Cristina Chiva; Daniel Balateu-Paños; Martí Colom-Cadena; Gemma Gomez-Giro; Laia Muñoz; Marta Querol-Vilaseca; Jordi Pegueroles; Lorena Rami; Albert Lladó; José L Molinuevo; Mikel Tainta; Jordi Clarimón; Tara Spires-Jones; Rafael Blesa; Juan Fortea; Pablo Martínez-Lage; Raquel Sánchez-Valle; Eduard Sabidó; Àlex Bayés; Olivia Belbin
Journal:  Mol Cell Proteomics       Date:  2019-01-03       Impact factor: 5.911

8.  Amyloid: From Starch to Finish.

Authors:  Hannah L Krystal; David A Ross; Adam P Mecca
Journal:  Biol Psychiatry       Date:  2020-05-01       Impact factor: 13.382

9.  BDNF Val66Met moderates memory impairment, hippocampal function and tau in preclinical autosomal dominant Alzheimer's disease.

Authors:  Yen Ying Lim; Jason Hassenstab; Carlos Cruchaga; Alison Goate; Anne M Fagan; Tammie L S Benzinger; Paul Maruff; Peter J Snyder; Colin L Masters; Ricardo Allegri; Jasmeer Chhatwal; Martin R Farlow; Neill R Graff-Radford; Christoph Laske; Johannes Levin; Eric McDade; John M Ringman; Martin Rossor; Stephen Salloway; Peter R Schofield; David M Holtzman; John C Morris; Randall J Bateman
Journal:  Brain       Date:  2016-08-12       Impact factor: 13.501

Review 10.  Neurodegeneration and Alzheimer's disease (AD). What Can Proteomics Tell Us About the Alzheimer's Brain?

Authors:  Guillermo Moya-Alvarado; Noga Gershoni-Emek; Eran Perlson; Francisca C Bronfman
Journal:  Mol Cell Proteomics       Date:  2015-12-11       Impact factor: 5.911

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.